Targeting folate receptor alpha for cancer treatment.

Oncotarget · 2016 · PMC5239573 · PMID 27248175

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The median OS also showed a trend towards improvement [ 75 ], although the non-randomized study design precluded drawing any firm efficacy conclusion given the likely prognostic value of FR-alpha expression.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.